Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma
-
By
-
Shuang Xiang
-
Zhuomiao Ye
-
Yifan Dai
-
Shipeng Shang
-
Dan Yang
-
Tao Cheng
-
Chao Deng
-
Minghui Zhang
-
Mingzhu Yin
-
May 28, 2026
-
Clinical Scorecard: Characterization of Immune Biomarkers and Fusion Partner-Phenotype Relationships in NUT Carcinoma of the Thorax and Head and Neck
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | NUTM1 gene rearrangements and fusion partners contributing to phenotypic heterogeneity |
| Target Population | |
| Care Setting | |
Key Highlights
- NUT carcinoma is characterized by NUTM1 rearrangements and significant phenotypic heterogeneity.
- Diagnostic challenges arise due to under-recognition and misclassification of the tumor.
Guideline-Based Recommendations
Diagnosis
- NUT immunohistochemistry (NUT-IHC) demonstrating nuclear positivity is essential for diagnosis.
- Confirmatory testing with FISH or NGS is required to document NUTM1 rearrangement.
- Incorporate NUT-IHC into standard diagnostic workflows to improve recognition.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Current treatment options are evolving and may not be optimal, with robust clinical evidence for targeted therapies still developing.
Clinical Best Practices
- Incorporate NUT-IHC into diagnostic workflows to improve recognition.
- Consider the phenotypic heterogeneity when evaluating treatment options.
Related Resources & Content
